Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein, Inc. reports developments across its health care distribution, practice solutions, and dental technology businesses. The company serves office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites through business, clinical, technology, and supply chain solutions.
Recurring news themes include earnings releases, financial guidance, investor conference participation, board and executive governance updates, and product announcements from Henry Schein One. Recent technology coverage centers on Dentrix Ascend, a cloud-based dental platform that integrates practice management, clinical workflows, imaging, revenue cycle management, analytics, patient experience tools, and AI-enabled workflow capabilities.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.
Henry Schein One (NASDAQ:HSIC) released its 2026 Catalyst Index, a benchmarking report for DSOs, multi-location groups, and private practices. The data indicates that clinical performance and case acceptance, not scale alone, drive predictable growth, with top performers achieving 75% case acceptance vs. a 45% industry average.
The Index also shows patient retention declining from 72% to 64% year over year, suggesting operational efficiency gains are not translating into long-term loyalty. The report is available in tailored editions for DSOs and private practices and debuts at CDA Anaheim.
Henry Schein (Nasdaq: HSIC) reported Q1 2026 results: total net sales $3.4B (+6.3% vs. Q1 2025) and Adjusted EBITDA $289M. GAAP diluted EPS was $0.92 and non-GAAP diluted EPS was $1.32. The company reaffirmed 2026 sales, non-GAAP EPS of $5.23–$5.37, and Adjusted EBITDA guidance, and expects >$200M operating income improvement, with a $125M run-rate by year-end 2026.
Henry Schein (NASDAQ:HSIC) will present at two investor conferences in May 2026: the Bank of America Healthcare Conference in Las Vegas on May 13 at 2:20 p.m. PT and the Stifel Jaws & Paws Conference in New York City on May 27 at 3:00 p.m. ET.
Both presentations will be available via live webcast at the company investor website, with replays posted after each event.
Henry Schein One (HSIC) launched the Next Generation Clinical Workflow on April 30, 2026: a voice-driven, AI-enabled upgrade to Dentrix Ascend that integrates imaging, charting, diagnostics, and treatment planning into a single chairside workflow.
The platform leverages AWS and platform data (100,000+ locations, 120M+ claims processed, 191M eligibility checks, 22M digital forms) to power features like Image Verify, Voice Notes, Voice Perio, and Detect AI as clinician-facing detection aids used alongside practitioner judgment.
Henry Schein One (HSIC) added a Model Context Protocol (MCP) layer to Dentrix Ascend, enabling practices, DSOs, and developers to query data in natural language, run pre-built AI agents, and build custom workflows within the existing platform.
The platform cites reach across >100,000 locations and large clinical and operational datasets powering immediate no-code results; orchestration access rolls out after THRIVELIVE with broader availability later this year.
Henry Schein (Nasdaq: HSIC) will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026 and will host a live webcast conference call beginning at 8:00 A.M. ET.
Speakers include CEO Frederick M. Lowery and SVP & CFO Ronald N. South. Investors can access the live webcast via the company’s investor webcasts page and a replay will be posted after the presentation.
Henry Schein (Nasdaq: HSIC) will reduce its Board of Directors from fifteen to ten members after the 2026 Annual Meeting on May 21, 2026. Stanley M. Bergman will retire after 44 years on the board and be named Chairman Emeritus.
Four additional directors will not stand for reelection, and ten incumbent directors are nominated for election to the reduced board, which the board says preserves experience and diverse perspectives.
Henry Schein (Nasdaq: HSIC) was named one of the 2026 World's Most Ethical Companies® by Ethisphere for the 15th consecutive year, part of the program's 20th annual class. The company highlighted ethics, governance, and its 25-year Henry Schein Cares program, plus nearly $18 million in 2025 cash and product support.
The recognition reflects documented programs across governance, compliance, training, third‑party risk, and social impact measured via Ethisphere’s Ethics Quotient®.
Henry Schein One (HSIC) unveiled the next era of Dentrix Ascend on March 10, 2026, launching three new packages—Ascend Essentials, Pro, and Accelerate—built on a unified, agentic AI platform to streamline clinical workflows, imaging, and revenue cycle management.
Key metrics: the platform serves >48,000 practices, 90% of the top 50 DSOs, supports ~100 million claims annually, and recorded 22 million digital forms and 191 million eligibility checks in 2025.